Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia

Hisamitsu Suzuki, Kohei Kawashima, Kazumasa Yamada, Saburo Minami, Yukio Kato, Mitsune Tanimoto, Hironori Yamada, Kenichi Isobe, Kiyotaka Hayashi, Hiroshi Yamaguchi, Junki Takamatsu, Eiji Watanabe, Yoshihisa Kodera, Hiroshi Shiku, Tadashi Kamiya, Ryuzo Ohno, Hiroshi Morishita, Shozo Yokomaku, Kazuko Yoshida, Michinori Ogura

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Eight patients with acute nonlymphocytic leukemia (ANLL) and five patients with acute lymphocytic leukemia were treated with aclacinomycin A. It was given daily by one-hour infusion in doses ranging from 0.33 to 0.70 mg/kg for seven to 20 days without other antileukemic agents. Two patients with ANLL achieved complete remission and one with ANLL achieved partial remission. Its major toxic effects were myelosuppression and gastrointestinal symptoms.

Original languageEnglish
Pages (from-to)111-118
Number of pages8
JournalJapanese journal of clinical oncology
Volume10
Issue number1
Publication statusPublished - Jun 1 1980

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia'. Together they form a unique fingerprint.

  • Cite this

    Suzuki, H., Kawashima, K., Yamada, K., Minami, S., Kato, Y., Tanimoto, M., Yamada, H., Isobe, K., Hayashi, K., Yamaguchi, H., Takamatsu, J., Watanabe, E., Kodera, Y., Shiku, H., Kamiya, T., Ohno, R., Morishita, H., Yokomaku, S., Yoshida, K., & Ogura, M. (1980). Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia. Japanese journal of clinical oncology, 10(1), 111-118.